After three packed days of company news, London's diary for Friday is much lighter, with quarterly numbers from drug makers AstraZeneca and Hikma getting the full attention of investors. Since the beginning of March, AstraZeneca shares have risen around 12% although over the past year they have remained frustratingly flat for investors and are not much higher than a peak reached around two years ago. Since February's final results, where full year guidance "failed to satisfy best hopes for the ...Den vollständigen Artikel lesen ...